This is a working overview of mass spectrometry, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-07-23 and is reviewed periodically as new material appears.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | About 1419.5 Da | Calculated from the fifteen-residue sequence |
| Residue count | 15 amino acids | Single-letter sequence GEPPPGKPADDAGLV |
| Compound class | Synthetic peptide | Produced by solid-phase synthesis |
| Synonyms | BPC 157; pentadecapeptide BPC 157 | Naming varies across suppliers and papers |
| Appearance | White to off-white powder | Typical form of the lyophilized material |
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
=== Taxonomy === Rhodiola rosea was first described by Pedanius Dioscorides in De Materia Medica. Many North American plants formerly included in R. rosea are now treated separately as Rhodiola integrifolia and Rhodiola rhodantha.
The low levels of progesterone with oral progesterone may also explain its differences in risk of breast cancer and venous thromboembolism relative to progestogens when added to estrogen therapy in postmenopausal women. Such risks are increased by progestins, which are PR agonists similar to progesterone, but have been found to be increased less or not at all by oral progesterone. Since typical clinical doses of oral progesterone achieve very low levels of progesterone, and progesterone therapy with luteal-phase progesterone levels has never been properly evaluated in sufficiently large clinical studies, it has been said that notion that progesterone somehow differs from progestins and does not increase the risk of breast cancer or venous thromboembolism is unsubstantiated. Moreover, in the absence of adequate data to the contrary, it would be reasonable to consider progesterone at least equivalent to progestins as a potential risk factor for such complications. Indeed, preclinical research suggests a carcinogenic role for progesterone in the breast, and the French E3N study observed a significantly higher risk of breast cancer with estrogen and oral progesterone therapy in postmenopausal women after long-term (>5-year) administration. This is potentially consistent with a weak proliferative effect of oral progesterone on the breasts such that a longer duration of exposure may be necessary for an increase in breast cancer risk to manifest.
=== 6 March === Sudan filed a case in the International Court of Justice (ICJ) against the United Arab Emirates, accusing it of complicity in genocide by providing weapons to the RSF. Canada imposed sanctions on al-Burhan and Hemedti, citing in part "an unwillingness on the part of the leaders to negotiate an end to the war".
=== ExpertDx === In 2026, after retiring from academic medicine, Laposata founded ExpertDx, Inc. The company provides expert interpretations of complex laboratory and diagnostic cases to ordering physicians nationwide, extending the diagnostic management team model beyond individual hospitals.
Umespirone (KC-9172) is a drug of the azapirone class which possesses anxiolytic and antipsychotic properties. It behaves as a 5-HT1A receptor partial agonist (Ki = 15 nM), D2 receptor partial agonist (Ki = 23 nM), and α1-adrenoceptor receptor antagonist (Ki = 14 nM), and also has weak affinity for the sigma receptor (Ki = 558 nM). Unlike many other anxiolytics and antipsychotics, umespirone produces minimal sedation, cognitive/memory impairment, catalepsy, and extrapyramidal symptoms.
Sources: en.wikipedia.org
Ulotaront (INNTooltip International Nonproprietary Name; developmental codes SEP-363856, SEP-856) is an investigational antipsychotic that is undergoing clinical trials for the treatment of schizophrenia and Parkinson's disease psychosis. The medication was discovered in collaboration between PsychoGenics Inc. and Sunovion Pharmaceuticals (which was subsequently merged into Sumitomo Pharma) using PsychoGenics' behavior and AI-based phenotypic drug discovery platform, SmartCube. Ulotaront is in phase III clinical trial for schizophrenia, phase II/III for generalized anxiety disorder and major depressive disorder, and discontinued for narcolepsy and psychotic disorders. Research has shown that ulotaront results in a greater reduction from baseline in the PANSS total score than placebo. Treatment with ulotaront, as compared with placebo, was also associated with an improvement in sleep quality. Ulotaront was awarded a Breakthrough Therapy designation due to its increased efficacy and greatly reduced side effects compared to current treatments.
== Properties == Native silk fibre is both strong and tough, and silkworm silk spun under controlled conditions approaches spider dragline silk in strength. Regenerated silk rarely matches it, because reprocessing disrupts the ordered molecular alignment produced during natural spinning, and the reconstituted material is correspondingly weaker. The extent of this loss depends on the format and the beta-sheet content, and matching the properties of native silk in regenerated form has not yet been fully resolved. Purified fibroin is well tolerated by living tissue and supports the attachment and growth of many cell types. The mild reaction associated with modern silk biomaterials results largely from purification: when sericin and other residues are removed the response is slight, whereas their presence provokes a stronger reaction. This is a large part of why degumming is emphasised in device manufacture. Many synthetic implants remain essentially inert in the body; silk does not. Protease enzymes such as chymotrypsin cleave it into peptides and amino acids that the body can absorb. The rate of degradation is not fixed; it can be set from a few weeks to more than a year by adjusting the beta-sheet content, the format and the porosity. This allows a scaffold to be designed so that it degrades at approximately the rate at which new tissue forms. Surgical silk is sometimes described as non-degradable, a term that reflects the slow loss of strength of a thick braided suture rather than any permanence of the protein itself.
=== Shear-induced mixing === The strong static stability of a CAD inversion layer usually inhibits turbulent mixing, even in the presence of vertical wind shear. However, if the shear strengthens in addition to a weakening of the inversion, the cold dome becomes vulnerable to shear-induced mixing. Unlike solar heating, this CAD event erosion happens from the top down. Mixing occurs when the depth of the northeasterly flow becomes increasingly shallow and strong southerly flow makes a downward progression resulting in high shear.
Susan E. Leeman (May 9, 1930 – January 20, 2026) was an American endocrinologist who was renowned for her research on peptides. Leeman was a professor in the Department of Pharmacology and Experimental Therapeutics at Boston University. She continued to work into her nineties and later served as the director of the Neuropeptide Laboratory in the Pharmacology Department at the Chobanian and Avedisian School of Medicine. Her work with substance P and neurotensin, both of which are peptides crucial to the function of the nervous, endocrine, and immune systems, led to her becoming considered one of the pioneers of neuroendocrinology. Her later research focused on substance P specifically and how it binds with its receptor. Leeman was elected as a member within the National Academy of Sciences in 1991 and received the academy's Fred Conrad Koch Award in 1994. Leeman was a member of the Endocrine Society, Society for Neuroscience, American Association for the Advancement of Science, and American Physiological Society.
Sources: en.wikipedia.org
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.
The number is an internal laboratory designation from the research group that first described the fragment. It does not encode a molecular weight, a receptor target, or a measured biological effect, and it carries no meaning outside the naming history of the compound.
It contains fifteen amino acid residues and has a calculated mass of roughly 1419.5 daltons. That places it in the short-peptide range, well below the size of small proteins, which affects how it is synthesized, purified, and analyzed.
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.